An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
BB-1701-G000-205
Phase 2 other active
Quick answer
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer for HER2 positive or HER2-low metastatic breast cancer is a Phase 2 program (other) at Eisai GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eisai GmbH
- Indication
- HER2 positive or HER2-low metastatic breast cancer
- Phase
- Phase 2
- Modality
- other
- Status
- active